Type 2 diabetes mellitus
Conditions
Interventions
Switching from DPP4 inhibitor to Luseogliflozin
Continuing of DPP4 inhibitor
Sponsors
Hokkaido University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) HbA1c 6.0-9.0%. 2) Patients with type 2 diabetes who have been taking DPP-4 inhibitors (except weekly agents) for 4 weeks. 3) Patients with hypertension(> 130/80 mmHg). 4) Written informed consent.
Exclusion criteria
Exclusion criteria: 1) Patients with taking SGLT2 inhibitors. 2) Hypersensitivity to Luseogliflozin. 3) Uncontrolled diabetic retinopathy 4) Severe liver dysfunction, renal dysfunction, or heart failure 5) Pregnancy, nursing woman or possibly pregnant woman 6) Severe diabetic ketosis, diabetic coma 7) Severe infection, pre and post operation , severe trauma 8) Deficiency of insulin secretion 9) BMI < 22kg/m2 10) eGFR < 30 ml/min 11) Patients with uncontrolled diet therapy. 12) Patients with irregular circadian rhythm. 13) Patients who thought to be inappropriate to enter this study for some reasons by physician's judgments
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in average of systolic blood pressure during the night-time section | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in average of diastolic blood pressure during the night-time section Changes in average of systolic and diastolic blood pressure during 24 hr Changes in average of systolic and diastolic blood pressure during the day-time section Blood pressure fluctuation in the night section relative to the day section M-value Trough of systolic and diastolic blood pressure for 1 hour before the next dose Changes in heart rate Changes in laboratory test value Relationship between blood pressure reduction and weight loss | — |
Countries
Japan
Contacts
Public ContactKyu Yong Cho
Hokkaido University Hospital Department of Medicine II/Clinical Research and Medical Innovation Center
Outcome results
None listed